Metformin Synergizes with BCL-XL/BCL-2 Inhibitor ABT-263 sorted by
relevance

Admin14.09.2021

Metformin Synergizes with BCL-XL/BCL-2 Inhibitor ABT-263

407
Admin28.07.2021

Metformin Synergizes with BCL-XL/BCL-2 Inhibitor ABT-263

7906
Admin05.10.2021

Metformin Synergizes with BCL-XL/BCL-2 Inhibitor ABT-263

7206
Admin30.09.2021

Metformin Synergizes with BCL-XL/BCL-2 Inhibitor ABT-263

5807
Admin08.09.2021

Metformin Synergizes with BCL-XL/BCL-2 Inhibitor ABT-263

4603
Admin03.08.2021

Metformin Synergizes with BCL-XL/BCL-2 Inhibitor ABT-263

1803
Admin17.08.2021

Metformin Synergizes with BCL-XL/BCL-2 Inhibitor ABT-263

3106
Admin12.08.2021

ABT-263: A Potent and Orally Bioavailable Bcl-2 Family

6206
Admin15.09.2021

ABT-263 (Navitoclax) | Potent Bcl-2 family inhibitor

3509
Admin10.09.2021

Navitoclax (ABT-263) | Bcl-2 inhibitor | Read Reviews

1704
Admin17.09.2021

Apoptosis is augmented in high-grade serous ovarian cancer

3105
Admin29.09.2021

ABT-263 (Navitoclax) | Potent Bcl-2 family inhibitor

1608
Admin19.09.2021

Selective BCL-2 family inhibitors enable the functional

80010
Admin17.08.2021

ABT-263 (Navitoclax) | Potent Bcl-2 family inhibitor

3504
Admin05.08.2021

ABT-263 (Navitoclax) | Potent Bcl-2 family inhibitor

25010
Admin16.07.2021

Inhibition of Bcl-xL triggers apoptosis of BCR-ABL1 þ

57010
Admin03.09.2021

ABT-263 (Navitoclax) | Potent Bcl-2 family inhibitor

2602
Admin06.08.2021

(PDF) The Bcl-2/xL inhibitor ABT-263 increases the

8402
Admin17.08.2021

BCL-X L - selective inhibitor A-1331852 enhances the

Admin10.10.2021

Bcl-2 Family - Apoptosis - Signaling Pathways

4503
Admin26.08.2021

(PDF) Effects of Bcl-2/Bcl-xL Inhibitors on Pulmonary

6001